Compare FTFT & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTFT | BMRA |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.3M |
| IPO Year | 2008 | 1995 |
| Metric | FTFT | BMRA |
|---|---|---|
| Price | $1.39 | $1.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 13.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,158,125.00 | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.40 |
| 52 Week High | $4.03 | $4.60 |
| Indicator | FTFT | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 39.33 |
| Support Level | $1.29 | $1.87 |
| Resistance Level | $1.60 | $2.40 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 28.79 | 22.99 |
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.